144 related articles for article (PubMed ID: 37673116)
21. Colorectal carcinoma with double somatic mismatch repair gene inactivation: clinical and pathological characteristics and response to immune checkpoint blockade.
Wang T; Lee LH; Vyas M; Zhang L; Ganesh K; Firat C; Segal NH; Desai A; Hechtman JF; Ntiamoah P; Weiser MR; Markowitz AJ; Vakiani E; Klimstra DS; Stadler ZK; Shia J
Mod Pathol; 2019 Oct; 32(10):1551-1562. PubMed ID: 31175329
[TBL] [Abstract][Full Text] [Related]
22. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
[TBL] [Abstract][Full Text] [Related]
23. Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.
Colle R; Radzik A; Cohen R; Pellat A; Lopez-Tabada D; Cachanado M; Duval A; Svrcek M; Menu Y; André T
Eur J Cancer; 2021 Feb; 144():9-16. PubMed ID: 33316636
[TBL] [Abstract][Full Text] [Related]
24. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
[TBL] [Abstract][Full Text] [Related]
25. First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case report.
Atiq MO; Pastor DM; Karzai F; Hankin AR; Turkbey B; Cordes LM; Brownell I; Liu Y; Chesnut GT; Madan RA
Front Oncol; 2023; 13():1126476. PubMed ID: 36937405
[TBL] [Abstract][Full Text] [Related]
26. Germline Testing of Mismatch Repair Genes Is Needed in the Initial Evaluation of Patients With Muir-Torre Syndrome-Associated Cutaneous Sebaceous Neoplasms: A Case Series.
Cohen PR; Kurzrock R
Cureus; 2023 Jan; 15(1):e33975. PubMed ID: 36824550
[TBL] [Abstract][Full Text] [Related]
27. A novel complex mutation in MSH2 contributes to both Muir-Torre and Lynch Syndrome.
Perera S; Ramyar L; Mitri A; Pollett A; Gallinger S; Speevak MD; Aronson M; Bapat B
J Hum Genet; 2010 Jan; 55(1):37-41. PubMed ID: 19911012
[TBL] [Abstract][Full Text] [Related]
28. Lynch Syndrome and MSI-H Cancers: From Mechanisms to "Off-The-Shelf" Cancer Vaccines.
Roudko V; Cimen Bozkus C; Greenbaum B; Lucas A; Samstein R; Bhardwaj N
Front Immunol; 2021; 12():757804. PubMed ID: 34630437
[TBL] [Abstract][Full Text] [Related]
29. Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142.
André T; Lonardi S; Wong KYM; Lenz HJ; Gelsomino F; Aglietta M; Morse MA; Van Cutsem E; McDermott R; Hill A; Sawyer MB; Hendlisz A; Neyns B; Abdullaev S; Memaj A; Lei M; Dixon M; Kopetz S; Overman MJ
Ann Oncol; 2022 Oct; 33(10):1052-1060. PubMed ID: 35764271
[TBL] [Abstract][Full Text] [Related]
30. Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy.
Balanescu DV; Donisan T; Palaskas N; Lopez-Mattei J; Kim PY; Buja LM; McNamara DM; Kobashigawa JA; Durand JB; Iliescu CA
Cardiovasc Pathol; 2020; 47():107211. PubMed ID: 32268262
[TBL] [Abstract][Full Text] [Related]
31. Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches.
Tan E; Sahin IH
Expert Rev Gastroenterol Hepatol; 2021 Jul; 15(7):735-742. PubMed ID: 33539189
[No Abstract] [Full Text] [Related]
32. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update.
Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC
Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582
[TBL] [Abstract][Full Text] [Related]
33. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
[No Abstract] [Full Text] [Related]
34. Frequency of Mismatch Repair Deficiency/High Microsatellite Instability and Its Role as a Predictive Biomarker of Response to Immune Checkpoint Inhibitors in Gynecologic Cancers.
Noh JJ; Kim MK; Choi MC; Lee JW; Park H; Jung SG; Joo WD; Song SH; Lee C
Cancer Res Treat; 2022 Oct; 54(4):1200-1208. PubMed ID: 34902958
[TBL] [Abstract][Full Text] [Related]
35. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).
Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Nakagawa H; Sotamaa K; Prior TW; Westman J; Panescu J; Fix D; Lockman J; Comeras I; de la Chapelle A
N Engl J Med; 2005 May; 352(18):1851-60. PubMed ID: 15872200
[TBL] [Abstract][Full Text] [Related]
36. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
37. Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report.
Sagawa T; Sato Y; Nagashima H; Takada K; Takahashi M; Hirakawa M; Hamaguchi K; Tamura F; Fujikawa K; Okamoto K; Kawano Y; Sogabe M; Miyamoto H; Takayama T
Front Immunol; 2023; 14():1203621. PubMed ID: 37492584
[TBL] [Abstract][Full Text] [Related]
38. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.
Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A
JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494
[TBL] [Abstract][Full Text] [Related]
39. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
[TBL] [Abstract][Full Text] [Related]
40. The frequency of Muir-Torre syndrome among Lynch syndrome families.
South CD; Hampel H; Comeras I; Westman JA; Frankel WL; de la Chapelle A
J Natl Cancer Inst; 2008 Feb; 100(4):277-81. PubMed ID: 18270343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
